These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32979732)

  • 1. Dermatographism associated with ocrelizumab.
    Raynowska J; Graves JS
    Mult Scler Relat Disord; 2020 Nov; 46():102505. PubMed ID: 32979732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab.
    Moreira Ferreira VF; Meredith D; Stankiewicz JM
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):. PubMed ID: 31454764
    [No Abstract]   [Full Text] [Related]  

  • 3. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
    Stahnke AM; Holt KM
    Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.
    Hartung HP; Berger T; Bermel RA; Brochet B; Carroll WM; Holmøy T; Karabudak R; Killestein J; Nos C; Patti F; Ross AP; Vanopdenbosch L; Vollmer T; Buffels R; Garas M; Kadner K; Manfrini M; Wang Q; Freedman MS
    Mult Scler Relat Disord; 2020 Nov; 46():102492. PubMed ID: 33039944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
    Emma C; Vesela P; Kay P; Huseyin H; Alison H; Mara S; Floriana A; Sara C
    Mult Scler; 2024 Jun; 30(7):893-897. PubMed ID: 38385208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two cases of meningitis associated with ocrelizumab therapy.
    Theriault M; Solomon AJ
    Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocarditis following ocrelizumab in relapsing-remitting MS.
    Faissner S; Schwake C; Gotzmann M; Mügge A; Schmidt S; Gold R
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32014890
    [No Abstract]   [Full Text] [Related]  

  • 10. Viral pericarditis following ocrelizumab in a multiple sclerosis patient.
    Miele G; Abbadessa G; Maida E; Bonavita S
    Neurol Sci; 2023 Aug; 44(8):2947-2949. PubMed ID: 37095363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.
    Zanetta C; Robotti M; Nozzolillo A; Sangalli F; Liberatore G; Nobile-Orazio E; Filippi M; Moiola L
    J Neurol Sci; 2020 Feb; 409():116603. PubMed ID: 31811986
    [No Abstract]   [Full Text] [Related]  

  • 12. Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
    Guerra T; Bollo L; Trojano M; Iaffaldano P
    Mult Scler; 2021 Nov; 27(13):2116-2118. PubMed ID: 34449289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis.
    Adamec I; Reiner Ž; Pećin I; Šućur N; Godan Hauptman A; Barun B; Gabelić T; Habek M
    Mult Scler Relat Disord; 2020 Oct; 45():102381. PubMed ID: 32653735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
    Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP
    Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis.
    Algahtani H; Shirah B; Alqahtani A; Abdelghaffar N; Makki S
    Acta Neurol Belg; 2024 Feb; 124(1):303-306. PubMed ID: 37301802
    [No Abstract]   [Full Text] [Related]  

  • 17. Parvovirus B19 infection in a patient with multiple sclerosis treated with ocrelizumab.
    Lattanzi S; Carlini G; Acciarri MC; Danni M; Silvestrini M
    Acta Neurol Belg; 2020 Feb; 120(1):231-232. PubMed ID: 31654393
    [No Abstract]   [Full Text] [Related]  

  • 18. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
    Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.
    Cohen BA
    Neurology; 2019 Feb; 92(9):435-436. PubMed ID: 30635476
    [No Abstract]   [Full Text] [Related]  

  • 20. Ocrelizumab (Ocrevus) for MS.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.